Biotech Values

[genisi]

OMRI - The patient experienced post operative rebleeding, belongs to the Israeli phase II trial in the severe bleeding group. This was considered a serious adverse event and therefore I assume required an automatic suspension of phase II trials according to the protocol.
Since up to date, first 60 patients treated successfully with the fibrin pad and there were no red flags from preclinical animal data, I don't think it will kill the fibrin pad but will no more than slow or perhaps restrict its use in certain operation (don't know what kind of surgical procedure was that patient undergoing).
I still see the fibrin pad as OMRI's next big product, with potential broad utility and addressing an unmet need in the hemostats market.